Difference in susceptibility to MxA protein between a coxsackievirus B1 isolate and prototype, impact of serial cell culture passage

Journal of Medical Virology

Volumn 82, Issue 3, 2010, Pages 424-432

  Chehadeh, Wassim ^a   Abdulkareem, Hayfaa A ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Antiviral activity; Clinical isolate; Enteroviruses; MxA protein; Type I interferon; Vero cells

Indexed keywords

MYXOVIRUS RESISTANCE PROTEIN A; PROTEIN VP1; VIRUS RNA;

ANTIBIOTIC SENSITIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS B; COXSACKIE VIRUS B1; COXSACKIE VIRUS INFECTION; ENTEROVIRUS; EXPERIMENTAL INFECTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; VERO CELL; VIRUS CAPSID; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION;

ADAPTATION, BIOLOGICAL; ANIMALS; CERCOPITHECUS AETHIOPS; CHILD; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS B, HUMAN; GTP-BINDING PROTEINS; HUMANS; SERIAL PASSAGE; VERO CELLS; VIRUS REPLICATION;

CARDIOVIRUS; COXSACKIEVIRUS; ENCEPHALOMYOCARDITIS VIRUS; ENTEROVIRUS; MENGO VIRUS; MIRIDAE; PICORNAVIRIDAE;

EID: 75449118121     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21713     Document Type: Article

References (40)

1. Archard LC, Bowles NE, Behan PO, Bell EJ, Doyle DJ. 1988a. Postviral fatigue syndrome: Persistence of enterovirus RNA in muscle and elevated creatine kinase. J R Soc Med 81:326-329.
2. Archard LC, Freeke C, Richardson P, Meany B, Olsen E, Morgan-Capner P, Rose M, Taylor P, Banner N, Yacoub M, Bowles N. 1988b. Persistence of enterovirus RNA in dilated cardiomyopathy: A progression from myocarditis. In: Schultheiss HP, editor. New concepts in viral heart disease. Berlin: Springer-Verlag KG. pp. 349-362.
3. Bergelson JM, Modlin JF, Wieland-Alter W, Cunningham JA, Crowell RL, Finberg RW. 1997. Clinical coxsackievirus B isolates differ from laboratory strains in their interaction with two cell surface receptors. J Infect Dis 175:697-700.
4. Blomqvist S, Paananen A, Savolainen-Kopra C, Hovi T, Roivainen M. 2008. Eight years of experience with molecular identification of human enteroviruses. J Clin Microbiol 46:2410-2413.
5. Burleson FG, Chambers TM, Wiedbrauk DL. 1992. Virology, a laboratory manual. San Diego: Academic Press, Inc. pp. 74-84.
6. Chehadeh W, Weill J, Vantyghem MC, Alm G, Lefebvre J, Wattre P, Hober D. 2000. Increased level of interferon-alpha in blood of patients with insulin-dependent diabetes mellitus: Relationship with coxsackie B infection. J Infect Dis 181:1929-1939.
7. Chezzi C, Dommann CJ, Blackburn NK, Maselesele E, McAnerney J, Schoub BD. 1998. Genetic stability of oral polio vaccine prepared on primarymonkey kidney cells or Vero cells - Effects of passage in cell culture and the human gastrointestinal tract. Vaccine 16:2031-2038.
8. Chieux V, Chehadeh W, Harvey J, Haller O, Wattre P, Hober D. 2001. Inhibition of coxsackievirus B4 replication in stably transfected cells expressing human MxA protein. Virology 283:84-92.
9. Clements GB, Galbraith DN, Taylor KW. 1995. Coxsackie B virus infection and onset of childhood diabetes. Lancet 346:221-223.
10. Dalwai A, Ahmad S, Pacsa A, Al-Nakib W. 2009. Echovirus type 9 is an important cause of viral encephalitis among infants and young children in Kuwait. J Clin Virol 44:48-51.
11. Diaz MO, Ziemin S, Le Beau MM, Pitha P, Smith SD, Chilcote RR, Rowley JD. 1988. Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci USA 85:5259-5263.
12. Dommergues M, Petitjean J, Aubry MC, Delezoide AL, Narcy F, Fallet-Bianco C, Freymuth F, Dumez Y, Lebon P. 1994. Fetal enteroviral infection with cerebral ventriculomegaly and cardiomyopathy. Fetal Diagn Ther 9:77-78.
13. Esfandiarei M, Boroomand S, Suarez A, Si X, Rahmani M, McManus B. 2007. Coxsackievirus B3 activates nuclear factor kappa B transcription factor via a phosphatidylinositol-3 kinase/protein kinase B-dependent pathway to improve host cell viability. Cell Microbiol 9:2358-2371.
14. Frese M, Kochs G, Meier-Dieter U, Siebler J, Haller O. 1995. Human MxA protein inhibits tick-borne Thogoto virus but not Dhori virus. J Virol 69:3904-3909.
15. Groarke JM, Pevear DC. 1999. Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants. J Infect Dis 179:1538-1541.
16. Haller O, Stertz S, Kochs G. 2007. The Mx GTPase family of interferon-induced antiviral proteins. Microbes Infect 9:1636-1643.
17. Höfling K, Kim KS, Leser JS, Chapman NM, Willian S, Gauntt CJ, Tracy S. 2000. Progress toward vaccines against viruses that cause heart disease. Herz 25:286-290.
18. Joo CH, Ahn J, Seo I, Kim YK, Kim D, Hong H, Lee H. 2005. Characterization of nonpolio enteroviruses recovered from patients with aseptic meningitis in Korea. Intervirology 48:97-103.
19. Jordan GW, Bolton V. 1985. Interferon-sensitive coxsackievirus variants in nature. J Interferon Res 5:289-296.
20. Karin M, Greten FR. 2005. NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749-759.
21. Kopp U, Meier-Dieter U, Koch E, Haller O. 1993. Human MxA protein in transfected Vero cells: No inhibition of paramyxoviruses. Glasgow, Scotland: IXth International Congress Virology. p. 174. Abstr P17-43.
22. Landis H, Simon-Jodicke A, Kloti A, Di Paolo C, Schnorr JJ, Schneider-Schaulies S, Hefti HP, Pavlovic J. 1998. Human MxA protein confers resistance to Semliki Forest virus and inhibits the amplification of a Semliki Forest virus-based replicon in the absence of viral structural proteins. J Virol 72:1516-1522.
23. Lee SH, Vidal SM. 2002. Functional diversity of Mx proteins: Variations on a theme of host resistance to infection. Genome Res 12:527-530.
24. Lévêque N, Norder H, Zreik Y, Cartet G, Falcon D, Rivat N, Chomel JJ, Hong SS, Lina B. 2007. Echovirus 6 strains derived from a clinical isolate show differences in haemagglutination ability and cell entry pathway. Virus Res 130:1-9.
25. Lin YC, Wu CN, Shih SR, Ho MS. 2002. Characterization of a Vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate. Vaccine 20:2485-2493.
26. Ortner B, Huang CW, Schmid D, Mutz I, Wewalka G, Allerberger F, Yang JY, Huemer HP. 2009. Epidemiology of enterovirus types causing neurological disease in Austria 1999-2007: Detection of clusters of echovirus 30 and enterovirus 71 and analysis of prevalent genotypes. J Med Virol 81:317-324.
27. Pevear DC, Tull TM, Seipel ME, Groarke JM. 1999. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 43:2109-2115.
28. Prather SL, Jenista JA, Menegus MA. 1984. The isolation of nonpolio enteroviruses from serum. Diagn Microbiol Infect Dis 2:353-357.
29. Rotbart HA. 2002. Treatment of picornavirus infections. Antivir Res 53:83-98.
30. Sawyer MH. 1999. Enterovirus infections: Diagnosis and treatment. Pediatr Infect Dis J 18:1033-1039.
31. Schmidtke M, Selinka HC, Heim A, Jahn B, Tonew M, Kandolf R, Stelzner A, Zell R. 2000. Attachment of coxsackievirus B3 variants to various cell lines: Mapping of phenotypic differences to capsid protein VP1. Virology 275:77-88.
32. Schmidtke M, Hammerschmidt E, Schüler S, Zell R, Birch-Hirschfeld E, Makarov VA, Riabova OB, Wutzler P. 2005. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: Antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment. J Antimicrob Chemother 56:648-656.
33. Schmidtke M, Merkle I, Klingel K, Hammerschmidt E, Zautner AE, Wutzler P. 2007. The viral genetic background determines the outcome of coxsackievirus B3 infection in outbred NMRI mice. J Med Virol 79:1334-1342.
34. Schneider-Schaulies S, Schneider-Schaulies J, Schuster A, Bayer M, Pavlovic J, Meulen V. 1994. Cell type-specific MxA-mediated inhibition of measles virus transcription in human brain cells. J Virol 68:6910-6917.
35. Staeheli P, Haller O. 1987. Interferon-induced Mx protein: A mediator of cellular resistance to influenza virus. Interferon 8:1-23.
36. Staeheli P, Pitossi F, Pavlovic J. 1993. Mx proteins: GTPases with antiviral activity. Trends Cell Biol 3:268-272.
37. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. 1998. How cells respond to interferons. Annu Rev Biochem 67:227-264.
38. Taffs RE, Chumakov KM, Rezapkin GV, Lu Z, Douthitt M, Dragunsky EM, Levenbook IS. 1995. Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions. Virology 209:366-373.
39. Verstrepen WA, Kuhn S, Kockx MM, Van De Vyvere ME, Mertens AH. 2001. Rapid detection of enterovirus RNA in cerebrospinal fluid specimens with a novel single-tube real-time reverse transcription-PCR assay. J Clin Microbiol 39:4093-4096.
40. Verstrepen WA, Bruynseels P, Mertens AH. 2002. Evaluation of a rapid real-time RT-PCR assay for detection of enterovirus RNA in cerebrospinal fluid specimens. J Clin Virol 25:S39-S43.